– USA, MA – Good Start Genetics®, Inc., a commercial-stage molecular genetic information company that has designed a proprietary technology platform to harness the power of next-generation DNA sequencing (NGS) to detect mutations that cause inherited genetic disorders, today announced the appointment of Charles F. Wagner, Jr. to the company’s board of directors.
“Charlie’s strong financial, management and operational experience within the life sciences industry will add a valuable perspective to our board of directors,” stated Don Hardison, president and chief executive officer of Good Start Genetics. “We look forward to benefiting from Charlie’s insights as we continue to provide physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders.”
Mr. Wagner is currently chief financial officer and executive vice president, finance and administration of Bruker Corporation (NASDAQ: BRKR), a global leader in analytical instrumentation and related solutions for life science, material science and applied markets. Prior to Bruker, Mr. Wagner served as chief financial officer and executive vice president, finance and administration of Progress Software Corporation (NASDAQ: PRGS), a provider of enterprise software located in Bedford, Mass. Earlier, Mr. Wagner served as chief financial officer and vice president of Millipore Corporation, a global provider of products and services in the life science tools market until it was acquired by Merck KGaA in July 2010. Mr. Wagner successfully managed all financial and operational aspects of the sale of Millipore to Merck KGaA, a transaction valued at nearly $7 billion. Prior to his full time employment at Bruker, Mr. Wagner served on the board of directors and as a member of the audit committee at Bruker and also served as a director of Bruker Energy & Supercon Technologies, Inc., a subsidiary of Bruker, where he was a member of the audit committee. Mr. Wagner holds a B.S. from Boston College and an MBA from Harvard University Graduate School of Business Administration.
“Good Start Genetics is seeking to set a new standard of care for genetic screening of inherited diseases,” said Mr. Wagner. “I am thrilled to be joining the Good Start Genetics team as they continue to deliver superior genetic carrier screening test offerings and expand in the reproductive medicine field.”
About GoodStart Select™
GoodStart Select is Good Start Genetics’ menu of genetic carrier screening tests that, for diseases such as cystic fibrosis, detects many more disease-causing mutations than traditional genotyping-based screening tests, regardless of patient ethnicity. The product of years of development and rigorous validation, GoodStart Select includes a suite of proprietary technologies, processes and algorithms designed to harness the power of next-generation DNA sequencing (NGS), to provide highly accurate and actionable tests resulting in higher mutation detection rates and fewer missed carriers.
To support its genetic carrier screening capabilities, Good Start Genetics has a dedicated team of customer care specialists and board certified genetic counselors who provide step-by-step support, from test selection through results, analysis and reporting. Good Start Genetics seeks to enable reproductive health specialists and their patients to have the highest degree of confidence in their genetic carrier screening results.
About Good Start Genetics, Inc.
Good Start Genetics is a commercial-stage molecular genetic information company focused on fundamentally transforming the standard of care in reproductive medicine by providing physicians and their patients with clinically relevant and actionable information concerning inherited genetic disorders. Good Start Genetics’ powerful, proprietary next-generation DNA sequencing (NGS) capabilities are supplemented by other proven genetic screening technologies and supported by its commitment to customer care and genetic counseling. Through GoodStart Select, the company provides a comprehensive and clinically actionable menu of genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.